

ASX RELEASE 5 January 2021

KAZIA PRESENTS TO HC WAINWRIGHT & CO BIOCONNECT

Sydney, 5 January 2021 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation to be made by our CEO, Dr James Garner, to the HC Wainwright & Co BIOCONNECT conference later today.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered GBM AGILE, a pivotal study in glioblastoma, in October 2020. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.


TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

For more information, please visit <u>www.kaziatherapeutics.com</u>.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

Board of Directors Mr Iain Ross Chairman, Non-Executive Director Mr Bryce Carmine Non-Executive Director Mr Steven Coffey Non-Executive Director Dr James Garner Chief Executive Officer, Managing Director





A company developing innovative, high-impact drugs for cancer

Presentation to HC Wainwright & Co BIOCONNECT

Dr James Garner Chief Executive Officer & Managing Director

5 January 2021

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.



Corporate Overview



	Company Description	Oncology-focused, late-clinical-stage, small-molecule biotechnology company, headquartered in Sydney, Australia
U g	Pipeline	Paxalisib – brain-penetrant PI3K / mTOR inhibitor about to enter international phase III for glioblastoma Cantrixil – cancer stem cell-targeting agent in phase I for ovarian cancer
	Financials	Listed on ASX (KZA) and NASDAQ (KZIA) with a market capitalization of ~US\$ 100 million ~US\$ 20M financing round completed October 2020



Investment Rationale

in Brain Cancer Clear Path to Commercialisation

World-Class Asset

- Paxalisib developed by Genentech, the world's most successful cancer drug company
- Well-proven mechanism of action, with unique differentiating factor of brain penetration
- Strong scientific rationale for development in brain cancer
- Encouraging clinical data emerging from US-based phase II study
- Potential best-in-class toxicity profile
- Ongoing FDA-endorsed GBM AGILE study will serve as pivotal study for registration
- US\$ 1.5 billion pa commercial opportunity in glioblastoma, with potential upside in other cancers
- High unmet medical need existing standard of care ineffective in two-thirds of patients
- 6x additional clinical studies at top tier US hospitals provide multiple shots on goal
- Optimised regulatory position with Orphan, Fast Track, and Rare Paediatric Disease Designations

Strong Corporate Story

- Kazia is a late-clinical-stage company, funded for phase III, with one of the leading assets in the global glioblastoma pipeline, and the potential to address a \$1.5 billion market
- Highly-efficient operating model, with ~80% of expenditure applied directly to R&D
- Lean team of internationally-experienced drug developers
- Good potential for partnering and / or M&A during remaining development of paxalisib




Program Overview

Paxalisib (GDC-0084) Brain Cancer



Treatment of brain cancer has improved little in recent decades, unlike other cancers



THERAPEUTICS

Paxalisib was designed specifically to overcome challenges associated with brain cancer treatment

Challenge

Blood-Brain Barrier

Most cancer therapies do not penetrate the BBB

Tumour Heterogeneity

Brain tumours exhibit a wide range of genetic aberrations

Toxicity

Some PI3K inhibitors have shown evidence of significant toxicity

Treatment Resistance Mechanisms

Tumour rapidly develops resistance to single agent treatment approaches

Clinical Population

GBM patients with recurrent disease often have significant morbidity

Approach

Brain-Penetration

Paxalisib is designed to cross the blood-brain barrier

Rational Target Selection

PI3K pathway is affected in 85-90% of GBM cases and many brain mets

Favourable Safety Profile

No evidence of GI, blood, renal, or CNS toxicities

Multiple Pharmacological Activities

Paxalisib active against all PI3K isoforms and also mTOR

Newly-Diagnosed Patients

Lead indication for paxalisib is firstline use in GBM

Commercially Attractive

Composition of matter patents through to 2031 in most jurisdictions

٠

٠

- Straightforward chemical synthesis; highly stable API; inexpensive manufacture
 - 15mg capsule presentation for oncedaily oral administration
- Limited toxicities and drug interactions
- Toxicology and CMC packages already largely sufficient for registration











Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer





Temozolomide is only FDA-approved drug for GBM; it is ineffective in \sim 65% of cases



15 to 22 months

~65% of patients don't respond to temozolomide

Extends overall survival from 12 to 13 months

For these patients, there is no effective pharmacological treatment currently available


temozolomide

Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003

Note: Temozolomide is only approved therapy for newly-diagnosed patients; Avastin (bevacizumab) is approved for use in recurrent setting



The PI3K class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier





The ongoing phase II study is designed to focus on newly-diagnosed patients, following radiotherapy

Step 1: Dose Optimisation

9 patients September 2018 – May 2019

Primary objective is to determine the appropriate dose for newly-diagnosed patients (phase 1 was in end-stage patients)

Fully-Recruited

- Top-line safety data: May 2019
- Interim efficacy data: Nov 2019
- Interim survival data: Apr 2020

Step 2: Expansion Cohort

21 patients June 2019 – February 2020

Primary objective is to generate supportive data for FDA and to provide confirmatory signals of efficacy in newly-diagnosed population

Fully-Recruited

- Interim efficacy data: Apr 2020
- Interim efficacy data: Jun 2020



Newly-diagnosed

patients with the unmethylated MGMT

to temozolomide)

of temozolomide

Primary objective is

efficacy (Step 2)

dose determination (Step 1) and signals of

 Paxalisib administered once daily, orally, as monotherapy in place

promotor (i.e. resistant







 \checkmark




University of Colorado Cancer Center

Note: timelines are estimated and subject to periodic revision based on recruitment performance and treatment effect



Latest phase II data compares well to historical data for temozolomide (existing standard of care)



Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like



A broad-based clinical program is underway across multiple forms of brain cancer

Paxalisib (GDC-0084)						
Primary Brain Cancer (brain cancer that begins in the brain)				Secondary Brain Cancer (brain cancer that spreads from elsewhere in the body)		
Glioblastoma	Glioblastoma	DIPG	Primary CNS Lymphoma	Brain Metastases	Breast Cancer Brain Mets	Brain Metastases
Most common and most aggressive brain tumour	Pivotal study for FDA registration	Highly aggressive childhood brain tumour	Treatment- resistant brain cancer	Cancer that has spread from any primary tumour	(combination with Herceptin®)	(combination with radiotherapy)
Phase II	Phase II / III	Phase I	Phase II	Phase II	Phase II	Phase I
NCT03522298	<u>NCT03970447</u>	NCT03696355	TBD	<u>NCT03994796</u>	NCT03765983	NCT04192981
KAZIA THERAPEUTICS	GLOBAL COALITION FOR ADAPTIVE RESEARCH	St. Jude Children's Research Hospital	DANA-FARBER	NIH NATIONAL CANCER INSTITUTE	DANA-FARBER	Memorial Sloan Kettering Cancer Center
L						
Firm de d				l 		

Funded by Kazia

Funded Primarily Through Partnerships and External Funding



GBM AGILE is the pivotal study for paxalisib in glioblastoma

What is GBM AGILE?

- A 'platform study', designed by the leading experts in brain cancer to expedite the approval of new drugs for glioblastoma
- Multiple drugs can be evaluated in parallel, saving time and money; Bayer's Stivarga (regorafenib) is the first drug to participate, and Kazia's paxalisib will be the second
- FDA has provided strong endorsement, saying that positive data from GBM AGILE will be suitable for product registration
- The study is currently active at approximately 28 hospitals in the United States and Canada and recruiting very well; expansion to Europe and China is expected in 1H CY2021
- Cutting-edge 'adaptive design' ensures that the study will only recruit the number of patients needed to reach an answer (up to 200 on paxalisib), avoiding redundancy and ensuring the fastest possible path to market

Who is Behind It?


GBM AGILE is sponsored by the Global Coalition for Adaptive Research (GCAR), a not-for-profit entity based in the United States

The study's scientific leadership includes world-leading experts in glioblastoma, among them several clinicians who have participated in clinical trials of paxalisib

GBM AGILE has received substantial grant funding, substantially reducing the cost of participation for companies such as Kazia



GBM AGILE is an adaptive multi-drug registrational study, with strong FDA support





GBM AGILE directly addresses the key challenges faced by small biotechs and their investors

Challenge

Limited Funding

Many biotech companies cannot afford world-class phase III studies

Long Study Timelines

Phase III studies can sometimes take many years to deliver a result

Regulatory Uncertainty

Small biotechs can struggle to get regulatory support for study design

Clinician Engagement

Competition for top hospitals and clinicians can be intense

Execution Risk

Small companies can struggle to operationalise a complex trial














Many of the world-leading experts in this disease are part of GBM AGILE

Live Study

GBM AGILE is already underway, recruiting well, and run by IQVIA

Approach

More Cost-Effective Approach

AGILE achieves huge efficiencies, and is partly grant-funded

Adaptive Study Design

AGILE is an 'adaptive' study, only recruiting the patients needed

Strong FDA Endorsement

FDA has provided written backing to the GBM AGILE study design

Kazia's successful phase II study

• Recruitment of up to 200 patients on paxalisib (but likely fewer due to adaptive design)


Indicative Parameters

Primary patient population essentially identical to

- Approximately equivalent number of patients in control group, making for a ~400 patient dataset
- Approximately 2-3 years to completion
- Approximately one-third cost of a comparable company-sponsored study



GBM AGILE is currently operational at 31 sites in US and Canada, and will open EU and China in CY2021





Source: www.gcaresearch.org

Recent regulatory achievements position paxalisib well as it moves towards commercialisation


	Glioblastoma Most common and most aggressive form of brain	DIPG Highly aggressive childhood brain cancer
Orphan Designation	<i>cancer</i> February 2018	August 2020
Rare Pediatric Disease Designation	(not applicable)	August 2020
Fast Track Designation	August 2020	for future consideration
Breakthrough Designation	for future consideration	for future consideration

Advantages to Kazia

- 'Data exclusivity' provides additional protection against competition beyond granted patents
- Waiver of up to US\$ 6 million in FDA fees at time of filing for marketing authorisations
- Eligibility for orphan grants
- Eligibility for priority review voucher at time of filing for marketing authorisation in DIPG (up to US\$ 350 million in value)
- Enhanced access to FDA, with scope for more frequent and informal meetings
- Ability to submit a 'rolling NDA' in which sections are given to FDA as they are generated, instead of waiting until the end of development



Brain cancer represents a significant commercial opportunity for paxalisib, with limited competition





Corporate Overview



A strong team brings international experience in big pharma and early-stage biotech

Board			Scientific Advisory Board		
Executive and small	Iain RossChairmanand Board roles in pharmabiotechRe	SANDOZ Silence Silence Silence		Professor Sir Murray Brennan Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Hospital, New York	Memorial Sloan Ke Cancer Center
6 years e	Bryce Carmine Deputy Chairman executive experience in Eli Lilly	Lilly		Dr Karen Ferrante Former Chief Medical Officer at Millennium Pharmaceuticals	THE TAKEDA ONCOLOGY OF
hartered	Steven Coffey Non-Executive Director <i>accountant with extensive gove</i>	rnance		Professor Peter Gunning Head of School of Medical Sciences at University of New South Wales	S UNSV
Physician	Dr James Garner Chief Executive Officer & Executive Director / MBA; Extensive drug ent experience	SANOFI Biogen EAIN & COMPANY		Professor Alex Matter Former Global Head of Oncology Research at Novartis	



Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation





Market Capitalisation	~US\$ 125 million		
Shares on Issue	~126 million		
Listing	ASX: KZA NASDAQ: KZIA (1:10 ratio)		
Key Shareholders	Willoughby Capital16%Platinum Asset Mgmt.9%Quest Asset Partners9%UniSuper6%Board & Mgmt.2%		
Balance Sheet (AU\$) (as at 30 Sept 20)	Cash:\$6.5 millionFY20 Spend:\$12.5 millionRunway:2Q CY2021Efficiency:~80% R&D		
	<i>Note: AU\$ 25 million financing completed in October 2020</i>		

Note: as at 30 November 2020, unless otherwise noted



Key Objectives for CY2021







Intensify partnering activity



Commence 'rolling NDA' filing activities



Key Milestones and Anticipated Newsflow

Execution of definitive agreement with GCAR for GBM AGILE pivotal study	October 2020	\checkmark
Further interim data from Kazia phase II glioblastoma trial	November 2020	\checkmark
Initial interim data from phase I DIPG trial at St Jude	November 2020	\checkmark
Initial interim data from phase II BCBM trial at Dana-Farber	H1 CY2021	
Commencement of recruitment to GBM AGILE pivotal study in glioblastoma	Q1 CY2021	
Commencement of recruitment to PNOC combination study in DIPG	Q1 CY2021	
Commencement of recruitment to phase II PCNSL study at Dana-Farber	Q1 CY2021	
Half-Year Financial Report	Q1 CY2021	
Initial interim data from phase II brain mets study by Alliance Group	H1 CY2021	
Initial interim data from phase I brain mets study at Sloan-Kettering	H1 CY2021	
Final data from Kazia phase II glioblastoma trial	H1 CY2021	

Note: all guidance is indicative, and subject to amendment in light of changing conference schedules, operational considerations, etc.





www.kaziatherapeutics.com